{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:34:21Z","timestamp":1790192061441,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81772840"],"award-info":[{"award-number":["81772840"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The immunotherapy has achieved some efficacy in triple-negative breast cancer (TNBC), but the benefit population is limited, primarily due to an abnormal immune microenvironment. Thus, it is necessary to explore new molecular targets to enhance the immunogenicity of TNBC cells and improve their responsiveness to immunotherapy. We found that a key component of the DNA repair system, Ataxia telangiectasia mutated (ATM), may function as an immune response inhibitor. In this study, the inverse correlation between ATM and CD8<jats:sup>+<\/jats:sup> T cells and tumor-infiltrating lymphocytes (TILs) was confirmed by immunochemical staining of 191 TNBC specimens. Subsequently, inhibition of ATM increased the expression of major histocompatibility complex I (MHC-I) and enhanced the infiltration and cytotoxic activity of CD8<jats:sup>+<\/jats:sup> T cells by Western blot and flow cytometry analysis. In addition, we further confirmed that the MHC-I upregulation induced by ATM inhibition depends on the activation of the c-Jun\/TNF-\u03b1\/p-STAT1 pathway. Animal studies have shown that ATM deficiency delays tumor growth and sensitizes tumors to PD-1 blockade and radiotherapy. This study reveals a new mechanism by which ATM negatively regulates MHC-I by inhibiting the c-Jun\/TNF-\u03b1\/p-STAT1 pathway in TNBC, and shows an important role in mediating CD8<jats:sup>+<\/jats:sup> T cells infiltration and regulating the \u201cheat\u201d of the immune microenvironment. The combination of ATM inhibitors with radiotherapy and Immune-checkpoint blockade (ICB) therapies may be a new strategy for TNBC treatment.<\/jats:p>","DOI":"10.1038\/s41419-025-07944-y","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T07:17:44Z","timestamp":1755501464000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Inhibition of ATM enhances the immunogenicity of triple-negative breast cancer by promoting MHC-I expression"],"prefix":"10.1038","volume":"16","author":[{"given":"Jiazhen","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqin","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanming","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiamei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yafang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumian","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengxia","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3753-2900","authenticated-orcid":false,"given":"Xiaojing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,18]]},"reference":[{"key":"7944_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00468-0","volume":"8","author":"P Zagami","year":"2022","unstructured":"Zagami P, Carey LA. Triple negative breast cancer: pitfalls and progress. NPJ Breast Cancer. 2022;8:95.","journal-title":"NPJ Breast Cancer"},{"key":"7944_CR2","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.3390\/pharmaceutics15071796","volume":"15","author":"O Obidiro","year":"2023","unstructured":"Obidiro O, Battogtokh G, Akala EO. Triple negative breast cancer treatment options and limitations: future outlook. Pharmaceutics. 2023;15:1796.","journal-title":"Pharmaceutics"},{"key":"7944_CR3","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","volume":"21","author":"P Schmid","year":"2020","unstructured":"Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21:44\u201359.","journal-title":"Lancet Oncol"},{"key":"7944_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01850-7","volume":"22","author":"Y Liu","year":"2023","unstructured":"Liu Y, Hu Y, Xue J, Li J, Yi J, Bu J, et al. Advances in immunotherapy for triple-negative breast cancer. Mol Cancer. 2023;22:145.","journal-title":"Mol Cancer"},{"key":"7944_CR5","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s00262-020-02736-z","volume":"70","author":"D Kwapisz","year":"2021","unstructured":"Kwapisz D. Pembrolizumab and atezolizumab in triple-negative breast cancer. Cancer Immunol Immunother. 2021;70:607\u201317.","journal-title":"Cancer Immunol Immunother"},{"key":"7944_CR6","first-page":"75","volume":"410","author":"K Chamoto","year":"2017","unstructured":"Chamoto K, Al-Habsi M, Honjo T. Role of PD-1 in immunity and diseases. Curr Top Microbiol Immunol. 2017;410:75\u201397.","journal-title":"Curr Top Microbiol Immunol"},{"key":"7944_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00386-1","volume":"8","author":"P Tarantino","year":"2022","unstructured":"Tarantino P, Corti C, Schmid P, Cortes J, Mittendorf EA, Rugo H, et al. Immunotherapy for early triple negative breast cancer: research agenda for the next decade. NPJ Breast Cancer. 2022;8:23.","journal-title":"NPJ Breast Cancer"},{"key":"7944_CR8","doi-asserted-by":"publisher","first-page":"435","DOI":"10.21037\/atm.2019.09.08","volume":"7","author":"L Bian","year":"2019","unstructured":"Bian L, Zhang H, Wang T, Zhang S, Song H, Xu M, et al. JS001, an anti-PD-1 mAb for advanced triple negative breast cancer patients after multi-line systemic therapy in a phase I trial. Ann Transl Med. 2019;7:435.","journal-title":"Ann Transl Med"},{"key":"7944_CR9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.matbio.2020.05.001","volume":"91-92","author":"M Yamauchi","year":"2020","unstructured":"Yamauchi M, Gibbons DL, Zong C, Fradette JJ, Bota-Rabassedas N, Kurie JM. Fibroblast heterogeneity and its impact on extracellular matrix and immune landscape remodeling in cancer. Matrix Biol. 2020;91-92:8\u201318.","journal-title":"Matrix Biol"},{"key":"7944_CR10","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1200\/JCO.2011.41.0902","volume":"31","author":"S Loi","year":"2013","unstructured":"Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013;31:860\u20137.","journal-title":"J Clin Oncol"},{"key":"7944_CR11","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1093\/annonc\/mdu112","volume":"25","author":"S Loi","year":"2014","unstructured":"Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol. 2014;25:1544\u201350.","journal-title":"Ann Oncol"},{"key":"7944_CR12","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.immuni.2022.04.016","volume":"55","author":"BW MacNabb","year":"2022","unstructured":"MacNabb BW, Tumuluru S, Chen X, Godfrey J, Kasal DN, Yu J, et al. Dendritic cells can prime anti-tumor CD8+ T cell responses through major histocompatibility complex cross-dressing. Immunity. 2022;55:982\u201397.","journal-title":"Immunity"},{"key":"7944_CR13","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.it.2024.01.009","volume":"45","author":"J Wang","year":"2024","unstructured":"Wang J, Lu Q, Chen X, Aifantis I. Targeting MHC-I inhibitory pathways for cancer immunotherapy. Trends Immunol. 2024;45:177\u201387.","journal-title":"Trends Immunol"},{"key":"7944_CR14","doi-asserted-by":"publisher","first-page":"e1637188","DOI":"10.1080\/2162402X.2019.1637188","volume":"8","author":"O Kepp","year":"2019","unstructured":"Kepp O, Zitvogel L, Kroemer G. Clinical evidence that immunogenic cell death sensitizes to PD-1\/PD-L1 blockade. Oncoimmunology. 2019;8:e1637188.","journal-title":"Oncoimmunology"},{"key":"7944_CR15","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1038\/s41590-019-0441-y","volume":"20","author":"V Verma","year":"2019","unstructured":"Verma V, Shrimali RK, Ahmad S, Dai W, Wang H, Lu S, et al. PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance. Nat Immunol. 2019;20:1231\u201343.","journal-title":"Nat Immunol"},{"key":"7944_CR16","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.3390\/cells12172181","volume":"12","author":"S Briguglio","year":"2023","unstructured":"Briguglio S, Cambria C, Albizzati E, Marcello E, Provenzano G, Frasca A, et al. New views of the DNA repair protein Ataxia-Telangiectasia mutated in central neurons: contribution in synaptic dysfunctions of neurodevelopmental and neurodegenerative diseases. Cells. 2023;12:2181.","journal-title":"Cells"},{"key":"7944_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2023.103662","volume":"28","author":"B Priya","year":"2023","unstructured":"Priya B, Ravi S, Kirubakaran S. Targeting ATM and ATR for cancer therapeutics: Inhibitors in clinic. Drug Discov Today. 2023;28:103662.","journal-title":"Drug Discov Today"},{"key":"7944_CR18","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.3390\/biom5031990","volume":"5","author":"Y Saito","year":"2015","unstructured":"Saito Y, Komatsu K. Functional role of NBS1 in radiation damage response and translesion DNA synthesis. Biomolecules. 2015;5:1990\u20132002.","journal-title":"Biomolecules"},{"key":"7944_CR19","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.dnarep.2013.10.004","volume":"12","author":"J Saha","year":"2013","unstructured":"Saha J, Wang M, Cucinotta FA. Investigation of switch from ATM to ATR signaling at the sites of DNA damage induced by low and high LET radiation. DNA Repair (Amst). 2013;12:1143\u201351.","journal-title":"DNA Repair (Amst)"},{"key":"7944_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116781","volume":"277","author":"S Du","year":"2024","unstructured":"Du S, Liang Q, Shi J. Progress of ATM inhibitors: Opportunities and challenges. Eur J Med Chem. 2024;277:116781.","journal-title":"Eur J Med Chem"},{"key":"7944_CR21","doi-asserted-by":"publisher","first-page":"4994","DOI":"10.1158\/1078-0432.CCR-12-3700","volume":"19","author":"X Guo","year":"2013","unstructured":"Guo X, Yang C, Qian X, Lei T, Li Y, Shen H, et al. Estrogen receptor \u03b1 regulates ATM Expression through miRNAs in breast cancer. Clin Cancer Res. 2013;19:4994\u20135002.","journal-title":"Clin Cancer Res"},{"key":"7944_CR22","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s10549-022-06679-0","volume":"196","author":"YM Song","year":"2022","unstructured":"Song YM, Qian XL, Xia XQ, Li YQ, Sun YY, Jia YM, et al. STAT3 and PD-L1 are negatively correlated with ATM and have impact on the prognosis of triple-negative breast cancer patients with low ATM expression. Breast Cancer Res Treat. 2022;196:45\u201356.","journal-title":"Breast Cancer Res Treat"},{"key":"7944_CR23","doi-asserted-by":"publisher","first-page":"e007474","DOI":"10.1136\/jitc-2023-007474","volume":"11","author":"WJ Jin","year":"2023","unstructured":"Jin WJ, Zangl LM, Hyun M, Massoud E, Schroeder K, Alexandridis RA, et al. ATM inhibition augments type I interferon response and antitumor T-cell immunity when combined with radiation therapy in murine tumor models. J Immunother Cancer. 2023;11:e007474.","journal-title":"J Immunother Cancer"},{"key":"7944_CR24","doi-asserted-by":"publisher","DOI":"10.1172\/JCI139333","volume":"131","author":"M Hu","year":"2021","unstructured":"Hu M, Zhou M, Bao X, Pan D, Jiao M, Liu X, et al. ATM inhibition enhances cancer immunotherapy by promoting mtDNA leakage and cGAS\/STING activation. J Clin Invest. 2021;131:e139333.","journal-title":"J Clin Invest"},{"key":"7944_CR25","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1186\/s13046-022-02469-0","volume":"41","author":"C Shi","year":"2022","unstructured":"Shi C, Qin K, Lin A, Jiang A, Cheng Q, Liu Z, et al. The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy. J Exp Clin Cancer Res. 2022;41:268.","journal-title":"J Exp Clin Cancer Res"},{"key":"7944_CR26","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1001\/jamaoncol.2022.5228","volume":"9","author":"TA Yap","year":"2023","unstructured":"Yap TA, Bardia A, Dvorkin M, Galsky MD, Beck JT, Wise DR, et al. Avelumab plus talazoparib in patients with advanced solid tumors: the JAVELIN PARP Medley nonrandomized controlled trial. JAMA Oncol. 2023;9:40\u201350.","journal-title":"JAMA Oncol"},{"key":"7944_CR27","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1016\/j.apsb.2021.01.003","volume":"11","author":"M Jiang","year":"2021","unstructured":"Jiang M, Jia K, Wang L, Li W, Chen B, Liu Y, et al. Alterations of DNA damage response pathway: biomarker and therapeutic strategy for cancer immunotherapy. Acta Pharm Sin B. 2021;11:2983\u201394.","journal-title":"Acta Pharm Sin B"},{"issue":"Jul","key":"7944_CR28","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41586-023-06069-6","volume":"619","author":"AVR Kornepati","year":"2023","unstructured":"Kornepati AVR, Rogers CM, Sung P, Curiel TJ. The complementarity of DDR, nucleic acids and anti-tumour immunity. Nature. 2023;619(Jul):475\u201386.","journal-title":"Nature"},{"key":"7944_CR29","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1172\/JCI67313","volume":"124","author":"L Deng","year":"2014","unstructured":"Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124:687\u201395.","journal-title":"J Clin Invest"},{"key":"7944_CR30","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/imm.13602","volume":"168","author":"Y Gao","year":"2023","unstructured":"Gao Y, Li Y, Lin Z, Zeng Y, Huang Z, Han L, et al. Ataxia telangiectasia mutated kinase inhibition promotes irradiation-induced PD-L1 expression in tumour-associated macrophages through IFN-I\/JAK signalling pathway. Immunology. 2023;168:346\u201361.","journal-title":"Immunology"},{"key":"7944_CR31","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1007\/s10616-016-9987-9","volume":"68","author":"YX Ren","year":"2016","unstructured":"Ren YX, Yang J, Sun RM, Zhang LJ, Zhao LF, Li BZ, et al. Viral IL-10 down-regulates the \u201cMHC-I antigen processing operon\u201d through the NF-\u03baB signaling pathway in nasopharyngeal carcinoma cells. Cytotechnology. 2016;68:2625\u201336.","journal-title":"Cytotechnology"},{"key":"7944_CR32","first-page":"2975","volume":"10","author":"C Agresti","year":"1998","unstructured":"Agresti C, Bernardo A, Del Russo N, Marziali G, Battistini A, Aloisi F, et al. Synergistic stimulation of MHC class I and IRF-1 gene expression by IFN-gamma and TNF-alpha in oligodendrocytes. Eur J Neurosci. 1998;10:2975\u201383.","journal-title":"Eur J Neurosci"},{"key":"7944_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216642","volume":"586","author":"C Liu","year":"2024","unstructured":"Liu C, Qian X, Yu C, Xia X, Li J, Li Y, et al. Inhibition of ATM promotes PD-L1 expression by activating JNK\/c-Jun\/TNF-\u03b1 signaling axis in triple-negative breast cancer. Cancer Lett. 2024;586:216642.","journal-title":"Cancer Lett"},{"key":"7944_CR34","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/cdd.2016.162","volume":"24","author":"Y Jiang","year":"2017","unstructured":"Jiang Y, Yu M, Hu X, Han L, Yang K, Ba H, et al. STAT1 mediates transmembrane TNF-alpha-induced formation of death-inducing signaling complex and apoptotic signaling via TNFR1. Cell Death Differ. 2017;24:660\u201371.","journal-title":"Cell Death Differ"},{"key":"7944_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202303818","volume":"62","author":"J Dong","year":"2023","unstructured":"Dong J, Miao J, Miao Y, Qu Z, Zhang S, Zhu P, et al. Small molecule degraders of protein tyrosine phosphatase 1B and T-cell protein tyrosine phosphatase for cancer immunotherapy. Angew Chem Int Ed Engl. 2023;62:e202303818.","journal-title":"Angew Chem Int Ed Engl"},{"key":"7944_CR36","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12929-021-00769-9","volume":"28","author":"YH Liang","year":"2021","unstructured":"Liang YH, Chen KH, Tsai JH, Cheng YM, Lee CC, Kao CH, et al. Proteasome inhibitors restore the STAT1 pathway and enhance the expression of MHC class I on human colon cancer cells. J Biomed Sci. 2021;28:75.","journal-title":"J Biomed Sci"},{"key":"7944_CR37","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1038\/s41416-023-02215-z","volume":"128","author":"J Guo","year":"2023","unstructured":"Guo J, Hu J, Zheng Y, Zhao S, Ma J. Artificial intelligence: opportunities and challenges in the clinical applications of triple-negative breast cancer. Br J Cancer. 2023;128:2141\u20139.","journal-title":"Br J Cancer"},{"key":"7944_CR38","doi-asserted-by":"publisher","first-page":"479","DOI":"10.6004\/jnccn.2020.7554","volume":"18","author":"TE Keenan","year":"2020","unstructured":"Keenan TE, Tolaney SM. Role of immunotherapy in triple-negative breast cancer. J Natl Compr Canc Netw. 2020;18:479\u201389.","journal-title":"J Natl Compr Canc Netw"},{"key":"7944_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2023.122067","volume":"296","author":"M Lin","year":"2023","unstructured":"Lin M, Cai Y, Chen G, Zhong H, Li B, Li T, et al. A hierarchical tumor-targeting strategy for eliciting potent antitumor immunity against triple negative breast cancer. Biomaterials. 2023;296:122067.","journal-title":"Biomaterials"},{"key":"7944_CR40","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.jconrel.2022.09.018","volume":"351","author":"T Wang","year":"2022","unstructured":"Wang T, Gao Z, Zhang Y, Hong Y, Tang Y, Shan K, et al. A supramolecular self-assembled nanomaterial for synergistic therapy of immunosuppressive tumor. J Control Release. 2022;351:272\u201383.","journal-title":"J Control Release"},{"key":"7944_CR41","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1089\/ars.2010.3694","volume":"15","author":"E Kotsiou","year":"2011","unstructured":"Kotsiou E, Brzostek J, Gould KG. Properties and applications of single-chain major histocompatibility complex class I molecules. Antioxid Redox Signal. 2011;15:645\u201355.","journal-title":"Antioxid Redox Signal"},{"key":"7944_CR42","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.coi.2020.05.008","volume":"64","author":"E Olson","year":"2020","unstructured":"Olson E, Geng J, Raghavan M. Polymorphisms of HLA-B: influences on assembly and immunity. Curr Opin Immunol. 2020;64:137\u201345.","journal-title":"Curr Opin Immunol"},{"key":"7944_CR43","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s13045-019-0812-8","volume":"12","author":"Q He","year":"2019","unstructured":"He Q, Jiang X, Zhou X, Weng J. Targeting cancers through TCR-peptide\/MHC interactions. J Hematol Oncol. 2019;12:139.","journal-title":"J Hematol Oncol"},{"key":"7944_CR44","doi-asserted-by":"publisher","first-page":"e002891","DOI":"10.1136\/jitc-2021-002891","volume":"9","author":"MV Negrao","year":"2021","unstructured":"Negrao MV, Skoulidis F, Montesion M, Schulze K, Bara I, Shen V, et al. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. J Immunother Cancer. 2021;9:e002891.","journal-title":"J Immunother Cancer"},{"key":"7944_CR45","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz3577","volume":"12","author":"SK Subudhi","year":"2020","unstructured":"Subudhi SK, Vence L, Zhao H, Blando J, Yadav SS, Xiong Q, et al. Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. Sci Transl Med. 2020;12:eaaz3577.","journal-title":"Sci Transl Med"},{"key":"7944_CR46","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1093\/annonc\/mdy551","volume":"30","author":"KM Heinhuis","year":"2019","unstructured":"Heinhuis KM, Ros W, Kok M, Steeghs N, Beijnen JH, Schellens JHM. Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors. Ann Oncol. 2019;30:219\u201335.","journal-title":"Ann Oncol"},{"issue":"Feb","key":"7944_CR47","doi-asserted-by":"publisher","first-page":"530","DOI":"10.3390\/cells12040530","volume":"12","author":"M Kciuk","year":"2023","unstructured":"Kciuk M, Ko\u0142at D, Ka\u0142uzi\u0144ska-Ko\u0142at \u017b, Gawrysiak M, Drozda R, Celik I, et al. PD-1\/PD-L1 and DNA damage response in cancer. Cells. 2023;12(Feb):530.","journal-title":"Cells"},{"key":"7944_CR48","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.3390\/cancers12102762","volume":"12","author":"X Zhao","year":"2020","unstructured":"Zhao X, Shao C. Radiotherapy-mediated immunomodulation and anti-tumor abscopal effect combining immune checkpoint blockade. Cancers (Basel). 2020;12:2762.","journal-title":"Cancers (Basel)"},{"issue":"May","key":"7944_CR49","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2021.1903827","volume":"18","author":"L Tagliaferri","year":"2022","unstructured":"Tagliaferri L, Lancellotta V, Fionda B, Mangoni M, Cas\u00e0 C, Di Stefani A, et al. Immunotherapy and radiotherapy in melanoma: a multidisciplinary comprehensive review. Hum Vaccin Immunother. 2022;18(May):1903827.","journal-title":"Hum Vaccin Immunother"},{"issue":"Mar","key":"7944_CR50","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1158\/1078-0432.CCR-13-1607","volume":"20","author":"CR Gil del Alcazar","year":"2014","unstructured":"Gil del Alcazar CR, Hardebeck MC, Mukherjee B, Tomimatsu N, Gao X, Yan J, et al. Inhibition of DNA double-strand break repair by the dual PI3K\/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma. Clin Cancer Res. 2014;20(Mar):1235\u201348.","journal-title":"Clin Cancer Res"},{"issue":"Jan","key":"7944_CR51","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1158\/0008-5472.CAN-03-2384","volume":"64","author":"M K\u00fchne","year":"2004","unstructured":"K\u00fchne M, Riballo E, Rief N, Rothkamm K, Jeggo PA, L\u00f6brich M. A double-strand break repair defect in ATM-deficient cells contributes to radiosensitivity. Cancer Res. 2004;64(Jan):500\u20138.","journal-title":"Cancer Res"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07944-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07944-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07944-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T06:46:15Z","timestamp":1757400375000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07944-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,18]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7944"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-07944-y","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,18]]},"assertion":[{"value":"25 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All methods were approved by the Experimental Animal Ethics Committee of Tianjin Medical University Cancer Institute and Hospital (approval no. 2024074) and conducted following the Guide for the Care and Use of Laboratory Animals. This study was conducted in accordance with the Declaration of Helsinki, and written informed consent was obtained from all enrolled patients for data collection and follow-up purposes.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"624"}}